Speaker's Highlight

  • Don Sin University of British Columbia, St. Paul Hospital (Canada)
    Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
  • Parameswaran Nair McMaster University (Canada)
    Carolyn Calfee UCSF (U.S.A.)
  • Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
    David A. Schwartz University of Colorado School of Medicine (U.S.A.)
  • Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
    Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
  • Nicola Hananiah Baylor College of Medicine (U.S.A.)
    Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
  • Koichiro Asano Tokai University School of Medicine (Japan)
    Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
  • Konstantinos Kostikas University of Ioannina (Greece)
    Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)
  • Lung Transplantation for Connective Tissue Disease-Associated ILD

    Connective tissue disease-associated interstitial lung disease (CTD-ILD) can progress quietly while systemic symptoms compete for attention. Conditions such as systemic sclerosis, rheumatoid arthritis, inflammatory myopathies and mixed connective tissue disease may produce irreversible fibrosis, pulmonary hypertension and declining gas exchange. For selected patients, lung transplantation can offer meaningful survival and a return to everyday function.

    Transplant assessment is a process rather than a single referral decision. Respiratory physicians, rheumatologists, transplant surgeons, cardiologists, physiotherapists, pharmacists and allied health professionals must weigh disease trajectory, treatment response, infection risk, frailty and the patient’s ability to manage lifelong immunosuppression. In Australia, this work also involves practical issues such as Medicare-funded care, travel from regional areas and access to specialist centres in Sydney, Melbourne, Brisbane, Perth and other major cities.

    When CTD-ILD Becomes A Transplant Concern

    Referral should be considered before a patient becomes critically unwell. A steep fall in forced vital capacity or diffusing capacity, increasing oxygen requirements, declining six-minute walk distance, pulmonary hypertension or repeated hospital admissions can signal advanced disease. Waiting until mechanical ventilation or severe deconditioning develops may reduce the available options.

    Autoimmune disease adds complexity to the usual interstitial lung disease pathway. Systemic sclerosis may involve the oesophagus, causing reflux and aspiration, while inflammatory myopathy can affect swallowing and respiratory muscles. Rheumatoid arthritis may coexist with airway disease, pleural complications or infection risks from previous immunosuppressive therapy.

    A transplant team will usually review high-resolution CT imaging, pulmonary function tests, echocardiography, right-heart catheterisation when indicated, renal and liver function, vaccination status and nutritional condition. A swallowing assessment can be important where aspiration is suspected; information about endoscopic diverticulum management may be relevant when structural oesophageal problems complicate respiratory care.

    Patient Selection And Risk Assessment

    The central question is whether transplantation is likely to provide a better outcome than continued medical treatment, while accounting for operative and long-term risks. Age alone is not an automatic exclusion, but frailty, severe coronary disease, active malignancy, uncontrolled infection and major dysfunction in other organs may substantially alter candidacy.

    Autoimmune activity must be characterised rather than assumed. Some patients have stable extrapulmonary disease that can be managed after transplantation; others have renal, cardiac, gastrointestinal or neuromuscular involvement that changes the risk profile. The team may seek evidence that inflammatory disease is controlled and that immunosuppressive medicines can be adjusted safely.

    Australian patients may be assessed through state-based transplant networks and referred to centres such as Royal Prince Alfred Hospital in Sydney, The Alfred in Melbourne or Fiona Stanley Hospital in Perth, depending on clinical circumstances and local pathways. Someone travelling from regional Queensland, the Northern Territory or rural Western Australia may need a carefully planned period near the transplant centre, with accommodation, carer support and ongoing oxygen arrangements considered early.

    Surgery And Immunosuppression

    Lung transplantation may involve a single or bilateral graft, although bilateral transplantation is commonly considered when pulmonary hypertension, infection risk or disease severity makes it preferable. The operation is followed by intensive monitoring for primary graft dysfunction, infection, rejection, bleeding and problems with airway healing.

    Long-term treatment generally includes a calcineurin inhibitor, an antimetabolite and corticosteroids, adjusted according to kidney function, infection history, rejection surveillance and drug levels. Patients need regular bronchoscopies or other monitoring as advised, along with skin protection, cancer screening and prompt assessment of respiratory symptoms.

    The underlying connective tissue disease does not usually return in the transplanted lungs in the same form, because the new organs do not carry the original fibrotic process. However, systemic autoimmune activity can continue outside the lungs, and complications such as reflux, joint disease, muscle weakness or vascular problems still require specialist care.

    Living With A Transplant In Australia

    Rehabilitation begins before surgery where possible. Supervised exercise, nutritional support, vaccination review, smoking cessation and a written medication plan can improve readiness. After transplantation, patients need reliable access to pathology testing, pharmacy services and clinicians who understand interactions between immunosuppressants and common medicines.

    Australia’s geography makes continuity especially important. A patient from Hobart may need coordinated flights to a mainland centre, while someone from the Kimberley or Far North Queensland may face long travel, seasonal weather interruptions and limited local specialist coverage. Telehealth can support follow-up, but it does not replace examination, lung function testing or urgent review when symptoms change.

    Costs and logistics also shape recovery. Medicare supports many aspects of public hospital care, yet accommodation, transport, parking and time away from work can still place pressure on families. Australian transplant teams commonly involve social workers and transplant coordinators to help organise practical support, while DonateLife and state allocation systems underpin the availability of donor organs.

    Multidisciplinary Planning And Practical Monitoring

    Successful transplantation depends on shared decisions and clear communication. Rheumatology should remain involved after surgery, especially where there is systemic sclerosis, inflammatory myopathy or vasculitis. Respiratory physiotherapy, dietetics, psychology and pharmacy input can address issues that are easy to overlook during surgical planning.

    Conference education also helps clinicians compare approaches across the Asia-Pacific region, where patient populations, donor availability and health-service structures vary. The APSR congress material reflects the value of respiratory collaboration between specialists and professional organisations connected with APSR and KATRD.

    Clinical Checkpoints

    Before referral, the treating team should document:

    • Rate of lung function decline and oxygen requirement
    • Pulmonary hypertension, cardiac status and exercise tolerance
    • Reflux, swallowing difficulty and aspiration risk
    • Renal function, infection history and previous immunosuppression

    After transplantation, practical monitoring includes:

    • Tacrolimus or other immunosuppressant levels as prescribed
    • Fever, cough, breathlessness or a sudden fall in exercise capacity
    • Vaccination, skin checks and age-appropriate cancer screening
    • Adherence, mental wellbeing, nutrition and rehabilitation progress

    The best time to discuss transplantation is usually while the patient can still walk, participate in rehabilitation and make informed choices. For Australians living with CTD-ILD, early referral to a transplant-capable respiratory service allows medical risks, family support and travel realities to be addressed together. A practical takeaway is to begin transplant conversations when decline is evident but before severe deconditioning or an emergency admission narrows the available choices.

    Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
  • Mona Bafadhel King’s College London (United Kingdom)
    David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
  • James Chalmers University of Dundee (United Kingdom)
    David Price University of Aberdeen (United Kingdom)

Copyright ⓒ APSR2022 all rights reserved

APSR Congress Privacy Policy